JNJ Jan 2025 120.000 call
| Previous Close | 40.65 |
| Open | 40.45 |
| Bid | 39.20 |
| Ask | 42.50 |
| Strike | 120.00 |
| Expire Date | 2025-01-17 |
| Day's Range | 40.45 - 40.65 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 23 |
ZacksHere is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Simply Wall St.Johnson & Johnson (NYSE:JNJ) Seems To Use Debt Quite Sensibly
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Motley FoolBuy the Dip On These Warren Buffett Stocks
If you're like Warren Buffett, you favor solid companies that perform over the long term -- and, at the same time, reward investors with passive income. Buffett has made his fortune -- and the fortune of others as Berkshire Hathaway chairman -- by sticking to that idea. Well, an opportunity is here for two Buffett favorites.
BloombergTylenol-Maker Kenvue Poised to Get Wall Street Ratings After IPO
(Bloomberg) -- Kenvue Inc., the consumer health business that Johnson & Johnson spun off this month, will be eligible for ratings from a slew of major Wall Street banks next week, offering a chance to see how analysts are assessing initial public offerings amid the latest equities volatility and recession worries. Most Read from BloombergBiden, McCarthy Forge Debt Deal in Bid to Avert US DefaultWorld’s Richest Man Throws In Towel on Beverly Hills HotelKey Takeaways From Deal Biden, GOP Sealed to
ZacksBristol Myers (BMY) Thrombosis Drug Gets Fast Track Designation
Bristol Myers (BMY) obtains Fast Track Designation from the FDA for milvexian, which is being developed in collaboration with Johnson and Johnson's Janssen.
Motley FoolWant Passive Income Forever? Buy These 2 Magnificent Stocks Now
Many investors actively seek dividend stocks, and who can blame them? Choosing the right dividend stocks is arguably the best way to avoid this risk: Not all dividend stocks are created equal. With that said, let's turn our attention to two companies that are practically passive income machines and will likely continue rewarding shareholders with payout increases for a long time: Johnson & Johnson (NYSE: JNJ) and Apple (NASDAQ: AAPL).
ZacksSolid Earnings Fuel Potential Bull Market in Medical Devices
CNBC's Jim Cramer predicts a booming bull market for medical devices, with positive earnings reports across the space. INMD, JNJ, ISRG and GEHC can emerge as potential winners.
Motley FoolA Challenger to J&J's Top Blockbuster Is on the Way. Here's What You Need to Know.
When you think of Johnson & Johnson (NYSE: JNJ), you may think of shampoo and Band-Aids. In fact, J&J is in the process of spinning off that business into an entity called Kenvue. What is J&J's top revenue driver?
- Simply Wall St.
Is There An Opportunity With Johnson & Johnson's (NYSE:JNJ) 22% Undervaluation?
Key Insights The projected fair value for Johnson & Johnson is US$202 based on 2 Stage Free Cash Flow to Equity Johnson...
ZacksJohnson & Johnson (JNJ) Stock Moves -0.1%: What You Should Know
Johnson & Johnson (JNJ) closed the most recent trading day at $156.66, moving -0.1% from the previous trading session.
Motley FoolBetter Buy: Medtronic vs. Johnson & Johnson
Medtronic (NYSE: MDT) and Johnson & Johnson (NYSE: JNJ) are perfect examples of this type of winning long-term investment. Medtronic sells devices worldwide related to diabetes, cardiovascular, neuroscience, and surgery. Thanks to its vast portfolio, Medtronic has increased earnings over time.
- Reuters
UPDATE 2-Amgen settles patent lawsuit over biosimilar of J&J's big-selling Stelara
Johnson & Johnson has settled its lawsuit over Amgen Inc's proposed biosimilar version of J&J's top-selling treatment Stelara for psoriasis and other autoimmune conditions, according to a filing in Delaware federal court. Amgen said in a statement on Tuesday that the settlement terms are confidential, but it will allow the company to sell its biosimilar of Stelara "no later than January 1st, 2025."
ReutersAmgen settles patent lawsuit over biosimilar of J&J's big-selling Stelara
(Reuters) -Johnson & Johnson has settled its lawsuit over Amgen Inc's proposed biosimilar version of J&J's top-selling treatment Stelara for psoriasis and other autoimmune conditions, according to a filing in Delaware federal court. Amgen said in a statement on Tuesday that the settlement terms are confidential, but it will allow the company to sell its biosimilar of Stelara "no later than January 1st, 2025." A J&J spokesperson said the company will "continue to defend the intellectual property associated with our medicines to protect our ability to innovate and develop life-changing therapies for patients."
Motley FoolBuying These 2 Stocks Is a Good Way to Hedge Against a Market Crash
Johnson & Johnson (NYSE: JNJ) and Dollar General (NYSE: DG) are traditionally strong, defensive stocks. Both companies deliver stable earnings, low volatility, and -- last but certainly not least -- dependable dividends. Johnson & Johnson stock traditionally has done well during downturns compared to the rest of the market.
Motley FoolGot $1,000? 5 Buffett Stocks to Buy and Hold Forever
It's hard to beat Warren Buffett's knack for making money, which is why so many investors keep a sharp eye on the stocks Buffett buys through his holding company, Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B). Of the nearly 50 stocks Buffett currently owns, here are five you might want to buy now and hold forever. Johnson & Johnson (NYSE: JNJ) is one of the longest-held stocks in Buffett's portfolio, and there are solid reasons you also might want to buy and hold this healthcare stock.
Motley Fool3 Relatively Safe Stocks to Buy if a Recession Is on the Way
Here's why three Motley Fool contributors think that AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Johnson & Johnson (NYSE: JNJ) are relatively safe stocks to buy if a recession is declared this year. Prosper Junior Bakiny (AbbVie): It may be hard to believe that AbbVie is a safe stock right now.
Motley FoolKenvue Just IPO'd, but Is the Stock a Buy?
With its listing on the New York Stock Exchange on May 4 and the conclusion of its initial public offering (IPO) on May 8, Kenvue (NYSE: KVUE) is finally a separate entity from Johnson & Johnson (NYSE: JNJ). The IPO raised net proceeds of $4.2 billion, and it marks the birth of a new giant within the consumer health products industry. In case you aren't familiar, Kenvue owns the rights to dozens of popular consumer health brands like Listerine, Aveeno, Tylenol, Motrin, Baby Powder, and even Band-Aids.
ZacksJohnson & Johnson (JNJ) Down 2.2% Since Last Earnings Report: Can It Rebound?
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Motley Fool2 Dividend Stocks to Double Up On Right Now
The continued bear market in stocks has a silver lining. Johnson & Johnson (NYSE: JNJ) and Prologis (NYSE: PLD) are great stocks to double up on right now for those with a low allocation to these leading dividend payers. Meanwhile, investors who don't own them yet should consider adding them to their portfolio.
- Simply Wall St.
Should Income Investors Look At Johnson & Johnson (NYSE:JNJ) Before Its Ex-Dividend?
Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Johnson...
Motley Fool3 No-Brainer Stocks to Buy With $1,000 Right Now
This makes every sizable downturn in equities a buying opportunity for patient investors. What's more, most online brokerages have completely done away with commission fees and minimum deposit requirements, which makes it easier than ever for everyday investors to put their money to work on Wall Street. The first stock that makes for a smart buy with the major stock indexes well off their all-time highs is Alphabet (NASDAQ: GOOGL)(NASDAQ: GOOG), the parent company of internet search engine Google, streaming platform YouTube, and autonomous vehicle company Waymo, among other subsidiaries.
Motley FoolGot $5,000? These 3 High-Yielding Dividend Stocks Are Trading Near Their 52-Week Lows
If you're buying a dividend stock that's trading near its low for the year, it stands to reason that the yield is also higher than it would normally be. The tough part is ensuring you have found a quality stock. Three that qualify are Johnson & Johnson (NYSE: JNJ), Paychex (NASDAQ: PAYX), and Keurig Dr Pepper (NASDAQ: KDP).
- Reuters
AstraZeneca's Tagrisso, chemo combination shows promise in lung cancer trial
The combination of AstraZeneca's cancer drug, Tagrisso, with chemotherapy to treat patients with a type of lung cancer showed positive results in a late-stage trial, the company said on Wednesday. The drug maker said patients on the combined treatment showed a meaningful improvement in progression-free survival, or how long a patient lives without the disease getting worse after treatment, than patients given only Tagrisso. The trial was on patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer.
ReutersJ&J's proposed talc settlement would pay $400 million to US state AGs
Johnson & Johnson has set aside $400 million to resolve U.S. state consumer protection actions as part of its broader $8.9 billion effort to settle claims that its Baby Powder and other talc products cause cancer. J&J subsidiary LTL Management filed a bankruptcy plan in New Jersey late on Monday that details how the company intends to pay different types of cancer victims in a bankruptcy settlement. J&J has said that its talc products are safe and do not cause cancer.
Motley FoolKenvue Has Gone Public: Should You Buy the Stock?
Johnson & Johnson (NYSE: JNJ) officially spun off its consumer health business this month, creating the largest U.S. initial public offering since 2021. Kenvue (NYSE: KVUE) began trading as a stand-alone business and gives healthcare investors a new stock to potentially add to their portfolios. Although Kenvue is technically a separate company, Johnson & Johnson will still play a big role in its operations; the healthcare company will own a 90% stake in the business.
